| Literature DB >> 32087569 |
Kira Dobrochaeva1, Nailya Khasbiullina2, Nadezhda Shilova3, Nadezhda Antipova4, Polina Obukhova5, Tatiana Ovchinnikova1, Oxana Galanina1, Ola Blixt6, Horst Kunz7, Alexander Filatov8, Yuriy Knirel9, Jacques LePendu10, Sergey Khaidukov1, Nicolai Bovin11.
Abstract
To understand the role of human natural IgM known as antibodies against the carbohydrate epitope Tn, the antibodies were isolated using GalNAcα-Sepharose affinity chromatography, and their specificity was profiled using microarrays (a glycan array printed with oligosaccharides and bacterial polysaccharides, as well as a glycopeptide array), flow cytometry, and inhibition ELISA. The antibodies bound a restricted number of GalNAcα-terminated oligosaccharides better than the parent monosaccharide, e.g., 6-O-Su-GalNAcα and GalNAcα1-3Galβ1-3(4)GlcNAcβ. The binding with several bacterial polysaccharides that have no structural resemblance to the affinity ligand GalNAcα was quite unexpected. Given that GalNAcα is considered the key fragment of the Tn antigen, it is surprising that these antibodies bind weakly GalNAcα-OSer and do not bind a wide variety of GalNAcα-OSer/Thr-containing mucin glycopeptides. At the same time, we have observed specific binding to cells having Tn-positive glycoproteins containing similar glycopeptide motifs in a conformationally rigid macromolecule. Thus, specific recognition of the Tn antigen apparently requires that the naturally occurring "anti-Tn" IgM recognize a complex epitope comprising the GalNAcα as an essential component and a fairly long amino acid sequence where the amino acids adjacent to GalNAcα do not contact the antibody paratope; i.e., the antibodies recognize a spatial epitope or a molecular pattern rather than a classical continuous sequence. In addition, we have not found any increase in the binding of natural antibodies when GalNAcα residues were clustered. These results may help in further development of anticancer vaccines based on synthetic Tn constructs.Entities:
Keywords: Anti-Glycan antibodies; Cancer; Glycans; Natural antibodies; Tn antigen
Year: 2020 PMID: 32087569 DOI: 10.1016/j.molimm.2020.02.005
Source DB: PubMed Journal: Mol Immunol ISSN: 0161-5890 Impact factor: 4.407